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Abstract
Background: Pristane-treated mice chronically produce high levels of anti-ribonucleoprotein/Smith (anti-Sm/RNP)
and other lupus autoantibodies. The present study addressed how these autoantibody levels are maintained
over time.
Methods: Lupus was induced in BALB/c mice using pristane. Naïve B cells, switched memory B cells, switched
plasmablasts, and plasma cells were flow-sorted and total IgG and anti-U1A (RNP) autoantibodies were determined
with ELISA.
Results: B cells with a switched “memory-like” (CD19+CD138−IgM−IgD−) (sMB) phenotype were increased in
pristane-treated mice and expressed higher levels of Toll like receptor 7 (Tlr7) than cells with this phenotype from
untreated mice. Flow-sorted sMB cells from pristane-treated mice did not secrete IgG spontaneously, but were
hyper-responsive to both synthetic (R848) and natural (apoptotic cells) TLR7 ligands, resulting in increased IgG
production in vitro. The flow-sorted sMB cells also could be driven by R848 to produce IgG anti-U1A autoantibodies.
Production of IgG was strongly inhibited by both JSH-23 and SB203580, suggesting that the canonical NFκB and
p38 MAPK pathways, respectively, contribute to the TLR7 ligand hyper-responsiveness of sMB from pristane-treated
mice.
Conclusions: The switched memory B cell subset from pristane-treated mice is expanded and shows an increased
propensity to undergo terminal (plasma cell) differentiation in response to synthetic and natural TLR7 ligands. The
data suggest that the decreased clearance of apoptotic cells characteristic of pristane-treated mice might help
maintain high serum levels of anti-RNP/Sm autoantibodies.
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Background
Systemic lupus erythematosus (SLE) is characterized by
B cell hyperactivity and autoantibody production against
nucleic acid-associated proteins, such as anti-Smith/
ribonucleoprotein (anti-Sm/RNP), anti-DNA, and others
[1]. Selectivity for these autoantigens may relate to their
associated nucleic acids, which are ligands for toll-like re-
ceptors (TLR) [2–4]. TLR7 is involved in innate immunity
to pathogen-associated single-stranded RNA [5] and also
recognizes host RNA sequences including U1 RNA, the
RNA component of U1 small nuclear ribonucleoproteins
(snRNPs) recognized by anti-Sm/RNP autoantibodies [2].
Accumulating evidence implicates TLR7-driven type I
interferon (IFN-I) production as a key mediator of murine
lupus [6]. In experimental lupus induced by 2,6,10,14-tet-
ramethylpentadecane (TMPD, pristane), autoantibody
production and nephritis are abolished in mice lacking
either TLR7 or the IFN-I receptor [7]. TLR7 is IFN-I indu-
cible [8], suggesting that increased TLR7 expression may
contribute to B cell hyperactivity and autoantibody pro-
duction in SLE [9]. RNA-protein complexes can activate B
cells through dual engagement of the B cell receptor and
TLR7 [4]. For autoantibody production, TLR7 could be in-
volved in the initial breach of tolerance, the maintenance
of serological memory once tolerance has been broken, or
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the survival of autoreactive B cells [10, 11]. Various B cell
subsets implicated in autoantibody production, including
follicular, marginal zone, and B-1a/B-1b B cells, respond
differently to TLR7 signaling [12–14]. Moreover, TLR7
signaling could enhance autoantibody production by plas-
mablasts (PB) or plasma cells (PC) or could promote the
differentiation of memory B cells (MB) into antibody-
secreting PB/PC.
We previously reported that the bone marrow (BM) of
mice with pristane-induced lupus contains autoreactive
B cells specific for the RNP autoantigen U1A [15]. These
cells have some characteristics of switched memory B
cells (sMB), including the absence of surface IgM and
lack of spontaneous IgG secretion. Upon stimulation
with the TLR4 ligand lipopolysaccharide (LPS), they dif-
ferentiate into anti-U1A antibody-secreting cells. More
recently, we found that BM in SLE patients and in
pristane-treated mice contains numerous dead cells,
which might stimulate local TNFα production by en-
gaging TLR7 [16]. It is not known whether autologous
TLR7 ligands derived from dead cells can drive terminal
differentiation of anti-U1A MB.
In the present study, we found that sMB from
pristane-treated mice are hyper-responsive to the syn-
thetic TLR7 ligand (R848), probably resulting from in-
creased TLR7 expression due to IFN-I production. We
show that in pristane-treated mice, an expanded popula-
tion of sMB can become IgG-secreting PB in response
to R848 or apoptotic cells, raising the possibility that the
accumulation of dead cells in lupus tissues may help




Mice were bred and maintained under specific pathogen-
free conditions at the University of Florida Animal Facility.
BALB/cByJ mice were from Jackson Laboratory (Bar
Harbor, ME, USA). BALB/c TLR7−/− mice were provided
originally by Dr. Shizuo Akira and bred in our facility. To
induce lupus, 0.5 ml of pristane was administered by
intraperitoneal (i.p.) injection. Controls were treated with
PBS. Spleen was harvested 12 months after treatment.
There were two to six mice per group and experiments
were repeated separately at least three times. These
studies were approved by the Institutional Animal Care
and Use Committee, University of Florida.
Reagents and cell lines
R848 (TLR7 ligand) andCpG-BODN1826 (murineTLR9 lig-
and) were purchased from Invivogen (San Diego, CA, USA).
Lipopolysaccharide (LPS, TLR4 ligand from Salmonella Min-
nesota) was from Sigma-Aldrich(St. Louis, MO). Recombin-
ant murine BAFF was from Biolegend (San Diego, CA).
ODN2088 andODN20958were fromMiltenyi Biotec GmbH




actinomycin D (7-AAD) was obtained from BD Bioscience
(San Jose, CA, USA). The non-secreting mouse myeloma
cell line SP2/0 was obtained from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA). The murine
anti-U1-70 K (RNP) hybridoma cell line 2.73 was a gift of
Dr. Sally Hoch [17]. Additional hybridomas included 172.4
(murine anti-CD100, ATCC), 11B11 (rat IgG1 anti-mouse
IL-4, ATCC), Pab101 (murine IgG2a anti-SV40 large T
antigen, ATCC), 111 (murine IgG1 anti-Ku), and 162
(murine IgG2a anti-Ku).
Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was isolated with TRIZOL reagent (Sigma-
Aldrich). cDNA was synthesized using the Superscript II
First-Strand Synthesis kit (Invitrogen) according to the
manufacturer’s protocol. Real-time PCR was carried out
as described [16]. Primer sequences were as follows:
TLR1 forward, CATTCCTGAGGTCCCTGCTA, reverse,
GATGCACAGCTCCTTGGTTT; TLR2 forward, CACC
AAGATCCAGAAGAGCC and reverse TAGGGGCTT
CACTTCTCTGC; TLR3 forward, ACAAAAGTCCCC
CAAAGGAG and reverse TGCAGTCTTTCCAGAGG
GAT; TLR4 forward, TGTCATCAGGGACTTTGCTG
and reverse GGACTCTGATCATGGCACTG; TLR5 for-
ward, GCACAGAAAGCATGAAGCTG and reverse GCC
TCTAAGGGCTCTCACCT; TLR6 forward, GAGGC
TATCCCAGAGGGACT and reverse GAAGGCTTTT
CTGGATTTTTCA; TLR7 forward, TGAGGGACTTCC
CACTAACA and reverse TTGGCTTTGGACCCCAG
TAG; TLR8 forward, CGCTTTATGGAAGATGGCAC
and reverse TGGATGTTAAGAGAGAAACAAACG;
TLR9 forward, GGCTTCAGCTCACAGGGTAG and re-
verse GAATCCTCCATCTCCCAACA; CIITA forward,
TCAAGCACATTGGAGCAGAG and reverse AGGTCC
TAGAGGTGGGCACT; UNC93B1 ATAGATGCCCACA
GCCAAGA and reverse TGCTGATGGGTATCAAC
GTG; 18 s forward, CGGCTACCACATCCAAGGAA and
reverse GCTGGAATTACCGCGGCT.
Flow cytometry
Monoclonal antibodies (mAbs) against mouse CD19 (clone
6D5, Pacific blue), CD138 (clone 281–2, APC), IgD (clone
11-26c.2a, PE) were from Biolegend(San Diego, CA). The
mAbs against mouse IgD (clone 11-26c.2a, FITC), I-A/I-E
(M5/114.15.2, PE), B220 (clone RA3-6B2, PerCP-Cy5.5)
and IgM (clone II/41, PerCP-cy5.5) were from BD Bio-
science. Cells were analyzed on LSRII flow cytometer (BD
Bioscience). Data were analyzed using FlowJo software
(Tree Star Inc., Ashland, OR, USA).
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Isolation of B cells and B cell subsets
Total B cells were positively selected from spleno-
cytes using a B cell magnetic bead isolation kit (Mil-
tenyi Biotec, Auburn, CA, USA). Purity was >95 %.
Murine B cell subpopulations were sorted with FAC-
Saria (BD Biosciences). The following B cell subpop-
ulations were sorted: naïve B cells (NB, CD19+CD138
−IgM+IgD+); switched “memory-like” B cells (sMB,
CD19+CD138−IgM−IgD−); switched plasmablasts (sPB,
CD19+CD138+IgM−IgD−); and plasma cells (PC,
CD19+CD138++IgM−IgD−). Purity was generally >95 %.
The sorted cells were cultured or lysed with Trizol for
harvesting RNA.
B cell culture and ELISA
Sorted B cells were seeded at 2.0 × 106 cells/ml with vari-
ous stimulation conditions: R848 (1 μg/ml), LPS (1 μg/ml)
and CpG 1826(10 μg/ml). In some experiments, ODN
2088 and ODN 20958 were added (0.1 μM) with R848.
Ten days later, culture supernatants were harvested and
tested for antibody production by ELISA. To test the role
of NFκB signaling and p38 mitogen-activated protein kin-
ase (MAPK) in IgG production, JSH-23 (NF-kB inhibi-
tor)[18] and SB203580 (p38 MAPK inhibitor) [19] was
added. B cells were treated with inhibitors for 1 h before
adding R848.
In some experiments, positively selected B cells
(2.0 × 106/ml) were co-cultured with apoptotic BW5147
(mouse thymoma cell line, from ATCC) for 10 d at a 1:1
ratio before testing the supernatants by ELISA. BW5147
cells were heat-shocked at 45 °C for 10 minutes and then
cultured 4 h before harvesting the apoptotic cells as
described [20].
Isolated B cell subsets (5 × 105 cells/ml) were cultured
for 10 days in RPMI-1640 supplemented with 10 % fetal
bovine serum with/without R848 (1 μg/ml). Total IgG/IgM
or IgG anti-U1A autoantibodies in supernatants were
quantified by ELISA as described [21].
Responses of murine hybridomas to TLR7 stimulation
SP2/0 and hybridoma cells were seeded at 4 × 104/ml
and stimulated for 3 days with R848 (1 μg/ml), LPS
(1 μg/ml), or CpG1826 (10 μg/ml) before harvesting cul-
ture supernatants for immunoglobulin ELISA. To assess
the effect of TLR ligands on proliferation, hybridoma
cells were loaded with carboxyfluorescein diacetate suc-
cinimidyl ester (CFSE, CellTrace CFSE cell proliferation
kit, Molecular Probes, Eugene, OR, USA) according to
the manufacturer’s protocol. CFSE-loaded cells were
cultured for 3 days in the presence of R848, LPS and
CpG1826. CFSE fluorescence intensity was evaluated by
flow cytometry as above.
Statistical analysis
Data are presented as mean ± SD. For normally dis-
tributed data, comparisons between mean values were
performed by the unpaired or paired two-tailed Student
t test using GraphPad (San Diego, CA, USA) Prism
version-5 software. Comparisons for non-normally dis-
tributed data were made using the t test; p <0.05 was
considered significant.
Results
In pristane-induced lupus, murine B cells that do not
spontaneously secrete anti-U1A (RNP) autoantibodies
can be driven to produce autoantibodies by culturing
with LPS [15]. We examined the B cell subset(s) that de-
velop into autoantibody-secreting cells and investigated
whether other TLR ligands also can promote terminal
differentiation of these cells.
Pristane treatment alters TLR7 responsiveness
Our previous study showed that TLR7 is necessary for
disease development in pristane-induced lupus [20]. To
assess the effect of pristane treatment on TLR ligand re-
sponsiveness, we cultured positively selected splenic
CD19+ B cells (>95 % purity) from pristane-treated and
PBS-treated BALB/c mice for 10 days with LPS, R848,
or CpG1826 and found that IgG production was stimu-
lated by all three TLR ligands (Fig. 1a). However, stimu-
lated IgG levels were substantially higher in culture
supernatants from pristane-treated vs. PBS-treated mice,
especially in the case of R848. In view of recent evidence
that the BM of both SLE patients and pristane-treated
mice contains numerous dead cells [16] along with IgG
anti-U1A memory-like B cells [15], we asked whether
purified B cells from pristane-treated mice could secrete
IgG in response to apoptotic cells (Fig. 1b). Splenic B
cells from PBS-treated mice produced little IgG when
co-cultured with apoptotic BW5147 murine thymoma
cells. In contrast, B cells purified from pristane-treated
mice increased their IgG production when co-cultured
with apoptotic cells (Fig. 1b). We hypothesized that
apoptotic cells may provide TLR7 ligands that stimulate
B cells from pristane-treated mice. To address this
question, TLR7 (ODN 20958) and TLR7/8/9 (ODN2088)
inhibitors were added into B cells cultured with R848 or
apoptotic BW5147 cells. Both ODN2088 and ODN20958
inhibited apoptotic cell-induced IgG production (Fig. 1c).
ODN20958 is a selective TLR7 antagonist, and its inhib-
ition of immunoglobulin secretion suggests TLR7 ligands
from apoptotic cells might stimulate B cells to pro-
duce IgG. That possibility was supported by looking
at TLR7−/− mice (Fig. 1d). As expected, R848 stimu-
lated IgG production by purified B cells from wild type,
but not TLR7−/− mice. Apoptotic cells also stimulated
IgG production by wild type mice. In contrast, IgG
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production increased only slightly when TLR7−/− B cells
were cultured with apoptotic cells, whereas wild type B
cells exhibited a stronger response (Fig. 1d).
Next we examined whether apoptotic cells could
stimulate B cells to produce IgG due to an intrinsic
hyper-responsiveness to TLR7 stimulation in pristane-
treated mice. Consistent with that possibility, IgG pro-
duction by R848-treated B cells from pristane-treated
mice was higher than by B cells from untreated controls
(Fig. 1e). Addition of B cell activating factor (BAFF) to
the cultures further enhanced IgG production in R848-
treated B cells from both pristane-treated and control
Fig. 1 Splenic CD19+ B cells from pristane-treated mice are hyper-responsive to synthetic toll-like receptor (TLR)7 ligand and apoptotic cells.
a Purified (magnetic beads) splenic CD19+ B cells from pristane-treated (one year) or PBS treated mice were stimulated by PBS or TLR ligands
R848 (TLR7), lipopolysaccharide (LPS) (TLR4) and CpG1826 (TLR9) for 10 days. IgG was measured in culture supernatants (ELISA). b Splenic CD19+ B
cells were stimulated by PBS or apoptotic BW5147 cells (Apo cells) (Apo cells: B cells = 1:1) and IgG was measured 10 days later by ELISA. c CD19+
B cells were stimulated by R848 or apoptotic cells with addition of ODN 2088 (0.1 μM) or ODN 20958 (0.1 μM), and IgG was measured 10 days
later by ELISA. d TLR7−/− and wild type mice were treated with pristane for 3 months. Purified splenic CD19+ B cells were stimulated with PBS,
R848 (1 μg/ml), or apoptotic BW5147 (Apo cells: B cells = 1:1). IgG in culture supernatants was measured 10 days later by ELISA. e R848 dose–
response curves for CD19+ B cells from pristane-treated vs. PBS treated mice. IgG levels were measured by ELISA. f CD19+ B cells were cultured
with R848 with/without the addition of recombinant murine BAFF (5 ng/ml, Biolegend) followed by measurement of IgG in culture supernatants
(ELISA). g Tlr7 and Unc93b1 mRNA expression level (compared to 18S rRNA) in pristane-treated vs. PBS treated splenic CD19+ B cells (Q-PCR):
*p <0.05; **p <0.01, paired Student t test. BAFF B cell activating factor
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mice (Fig. 1f ). There was little difference in Tlr7 gene
expression in total CD19+ B cells from pristane-treated
mice vs. untreated controls (Fig. 1g). Likewise, there was
little difference in the expression of Unc93b1 (Fig. 1g),
which restricts TLR7-mediated inflammation by biasing
endosomal TLR responses in favor of TLR9 [22].
Pristane treatment alters B cell subsets in spleen
We next examined the distribution of B cell subsets
in pristane-treated vs. control mice by staining for
CD19, CD138, IgM and IgD (Fig. 2a). Unexpectedly,
total CD19+CD138+ PB also decreased in pristane-treated
spleens (Fig. 2a, top). B cells with an sMB-like phenotype
(CD19+CD138−IgM−IgD−) were increased in spleens from
pristane-treated mice (Fig. 2a, bottom). In contrast,
CD19+CD138−IgM+IgD+ NB cells were decreased. As
there was not a clear separation between the NB
population and other cells that were CD19+CD138−
IgM−IgD+, we also analyzed this population and the
combined (CD19+CD138−IgM+ or -IgD+) population,
and found that cells with these phenotypes were all
decreased in pristane-treated mice (Fig. 2b).
Pristane treatment increases TLR7 expression in sMB and
responsiveness to TLR7 ligand
To further investigate the basis for the increased ability of
total B cells from pristane-treated mice to produce IgG
when stimulated with TLR7 ligands despite comparable
Tlr7 expression (Fig. 1), we asked whether there were
differences in Tlr7 expression or signaling in B cell subsets
from pristane-treated vs. PBS-treated mice. Tlr7 ex-
pression was quantified in highly purified B cell subsets
from BALB/c mice treated with pristane or PBS. NB
(CD19+CD138−IgM+IgD+), sMB (CD19+CD138−IgM−IgD−),
sPB (CD19+CD138+IgM−IgD−), and PC (CD19+/−CD138++
IgM−IgD−) were obtained by flow sorting (Fig. 3a). The
Fig. 2 B cell subsets in spleen from pristane-treated vs. PBS treated mice. Spleen cells from pristane-treated (1 year) and age-matched PBS treated
mice were stained with anti-CD19, CD138, IgM, and IgD antibodies and analyzed by flow cytometry. a Gating strategy for CD19+CD138+ plasmablasts
(PB) and CD19+/−CD138++ plasma cells (PC) (top) and CD19+CD138−IgM+IgD+ naïve B cells (NB), and CD19+CD138−IgM−IgD− switched-memory B cells
(sMB) (bottom) are shown on the left. Percentages of PB and PC in spleen from pristane-treated and untreated mice are on the top right and percentages
of NB and sMB in CD19+CD138− cells are on the bottom right. b The gating strategy for CD19+CD138−IgM−IgD+ and CD19+CD138−IgD+ cells is the same
as a. The percentage of CD19+CD138−IgM−IgD+ and CD19+CD138−IgD+ cells in CD19+CD138− cells in spleens from pristane-treated and untreated mice
are shown: *p <0.05; **p <0.01, Mann–Whitney test
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sorted PC population also contained some cells that were
CD138++IgM−IgD+. As intracellular major histocompati-
bility complex (MHC) class II molecules promote TLR
signaling in myeloid cells by acting as an adapter protein
that maintains Btk activation [23], we examined the ex-
pression of CIITA, a key transactivator of MHC II expres-
sion, in the B cell subsets. In untreated mice, splenic NB
expressed the highest levels of CIITA, followed by sMB,
sPB and PC (Fig. 3b, top). The same pattern was seen in
pristane-treated mice (data not shown). As expected,
CIITA expression decreased during terminal differenti-
ation to sPB and PC, confirming the efficacy of the purifi-
cation scheme. Consistent with CIITA expression, surface
MHC II expression also gradually decreased during B cell
maturation (Fig. 3b, bottom).
Quantification of Tlr7 expression by Q-PCR revealed
that TLR7 expression levels were higher in NB than in
other B cell subsets. However, expression levels were
comparable in PBS-treated vs. pristane-treated NB,
whereas Tlr7 was expressed at higher levels by sMB and
PC isolated from the spleens of pristane-treated mice vs.
PBS-treated controls (Fig. 3c). There was a similar trend
in sPB. Because duplication of the Tlr7 gene promotes
autoantibody production in BXSB male mice [24], we
examined the responsiveness of isolated splenic sMB
(Fig. 3e) and sPB/PC (Fig. 3d) to R848. Both sMB and
Fig. 3 Increased Tlr7 expression in B cells from pristane-treated mice. Spleen cells from untreated mice were stained with anti-CD19, CD138,
IgM, and IgD antibodies and four B cell subsets were identified by flow cytometry and sorted. a Gating strategy for isolating naïve B cells
(CD19+CD138−IgM+IgD+, NB), switched memory B cells: CD19+CD138−IgM−IgD−, sMB), switched plasmablasts (CD19+CD138+IgM−IgD−, sPB)
and plasma cells (CD19+/−CD138++IgM−IgD−, PC). b Top, CIITA gene expression (Q-PCR) (compared to 18S rRNA) in PC, sPB, sMB, and NB subsets.
Bottom, spleen cells were stained with anti-CD19, CD138, IgM, IgD, and major histocompatibility complex (MHC) II and analyzed by flow cytometry.
Mean fluorescence intensity (MFI) of MHC II staining in these four B cell subsets is indicated. c Tlr7 gene expression (compared to 18S) in purified sMB,
sPB, PC, and NB subsets from pristane-treated and PBS-treated mice. d IgG production stimulated by R848 in sPB + PC isolated from pristane or
PBS-treated mice and cultured with R848 or PBS. IgG secretion in culture supernatants was measured at 10 days (ELISA). e IgG production stimulated
by R848 in sMB. f Tlr7 gene expression (Q-PCR) (compared to 18S) in magnetic bead-purified splenic CD19+ B cells from PBS-treated mice stimulated
by PBS, interferon (IFN)α (80U/ml), R848 (1 μg/ml) or IFNα (80U/ml) plus R848 (1 μg/ml) for 6 h: *p <0.05, **p <0.01, Mann–Whitney test
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sPB/PC from pristane-treated mice produced more IgG
upon R848 stimulation than the same B cell subsets
from PBS-treated controls. As IFN-I plays a key role in
pristane-induced lupus [7], we examined its effects on
Tlr7 expression in B cells. Purified splenic B cells from
PBS-treated mice were stimulated with IFNα, R848 or
R848 + IFNα for 6 h. IFNα alone significantly increased
Tlr7 expression (Fig. 3f ). Although R848 alone did not
increase Tlr7 expression, it acted synergistically with
IFNα to further increase Tlr7 expression. These data
suggest that the hyper-responsiveness of pristane-treated
B cells to R848 stimulation (Figs. 1e; 3d and e) is a con-
sequence of both the increased number of sMB (Fig. 2a)
and increased Tlr7 expression by this subset (Fig. 3c).
TLR7 agonist induces B cell proliferation and inhibits cell
death
We next compared the impact of TLR7 ligation on the
proliferation and survival of purified B cell subsets
(Fig. 4). To assess proliferation, splenic NB, sMB, sPB,
and PC from PBS-treated mice were labeled with CFSE,
cultured for 72 h with R848, and analyzed by flow
cytometry (Fig. 4a). All B cell populations responded,
with the greatest proliferation in the NB subset and the
least in the PC. The same pattern was seen using B cells
from pristane-treated mice, but proliferation was less
than in B cells from PBS-treated mice (not shown). As
TLR ligands can either induce apoptosis [25] or prevent
it [26], we examined the effect of TLR7 ligation on cell
death (Fig. 4b). Cells were cultured with R848 for 24 h,
stained with 7-AAD and annexin V, and analyzed by
flow cytometry. In PBS-treated mice, more than 50 % of
B cells in each subset were necrotic (7-AAD+) after 24 h
in culture. Addition of R848 decreased the percentage of
necrotic cells in each B cell subset (Fig. 4b). Among
these, NB were the most sensitive to R848, with the per-
centage of 7-AAD+ cells decreasing from 67.5–34.4 %.
The survival of sPB, sMB, and to a lesser extent PC, was
also improved by culturing with R848. Similarly, cultur-
ing B cells with R848 decreased the percentage of apop-
totic (annexin-V+/7-AAD−) cells (not shown).
TLR7 ligand strongly induces IgG production by sMB from
pristane-treated mice
We next examined the effect of R848 treatment on
immunoglobulin secretion by B cell subsets from
pristane-treated mice. IgG and IgM production by differ-
ent subsets varied substantially after 10 days of culture
with R848 (Fig. 4c). As expected, sPB and PC produced
IgG spontaneously but IgG secretion was enhanced in
the sPB subset by adding R848 (Fig. 4c left). In contrast,
NB and sMB did not secrete IgG spontaneously. How-
ever, sMB (but not NB) could be driven by R848 to de-
velop into IgG secreting cells (Fig. 4c left). NB secreted
IgM when cultured with R848 but did not switch class
(Fig. 4c right). Thus, NB, sMB, and sPB all responded to
R848, with the sMB subset showing the most significant
increase over baseline IgG secretion. These data suggest
that the expanded sMB subset in spleens of pristane-
treated mice (Fig. 2a, right) may have an enhanced
capacity to undergo R848-mediated differentiation into
antibody secreting cells as a consequence of its increased
Tlr7 expression (Fig. 3c).
Terminally differentiated PCs are unresponsive to
TLR7 agonist
PC from pristane-treated mice had increased Tlr7 ex-
pression (Fig. 3c), but did not substantially increase IgG
secretion after R848 treatment (Fig. 4c). To further
assess whether fully mature PCs respond to TLR7
ligands, we examined the murine plasma cell lines SP2/0
(non-secreting PC) and 2.73 (anti-RNP secreting PC)
(Additional file 1: Figure S1). Both cell lines expressed a
variety of TLRs, including Tlr4, Tlr7, and Tlr9 (Additional
file 1: Figure S1A). During terminal B cell differentiation,
PCs lose CD19, B220 and MHC II, and gain expression of
CD138 [27]. As shown in Additional file 1: Figure S1B,
SP2/0 and 2.73 were CD138+CD19−B220−I-A/I-E+/−, con-
sistent with a mature PC phenotype. The 2.73 hybridoma
and five additional hybridomas of various specificities
were cultured with R848, LPS, or CpG1826 for 3 days,
and IgG in culture supernatant was quantified by ELISA.
As shown in Additional file 1: Figure S1C, TLR4, 7, and 9
agonists had little or no effect on IgG production. There
also was little effect on proliferation (Additional file 1:
Figure S1D). Thus, although these terminally differen-
tiated PC lines expressed Tlr4,Tlr7, and Tlr9, they did not
increase their immunoglobulin secretion or proliferation
rate in response to TLR4, 7, or 9 agonists.
R848 stimulates anti-RNP autoantibody production
TLR7 plays a key role in generating murine autoantibody
responses against ribonucleoproteins [6, 10, 20]. How-
ever, it is unclear whether TLR7 is involved in the initial
activation of anti-RNP/Sm reactive NB to become sMB,
the terminal differentiation of sMB into PB/PC, or both.
Co-culture with apoptotic cells, containing natural
TLR7/9 ligands, enhanced IgG secretion by total B cells
from pristane-treated, but not control, mice (Fig. 1b)
and B cells from pristane-treated mice were hypersensi-
tive to R848 (Fig. 1e). We examined whether this also
was true of autoantibody-producing B cells. Anti-U1A
autoantibodies were measured in the culture superna-
tants of NB, sMB, sPB, and PC sorted from spleen cells
of pristane-treated, serum anti-U1A+ mice. Total splenic
CD19+ B cells produced IgG anti-U1A autoantibodies
after 10 days culture with R848, LPS, or CpG1826. They
responded more strongly to R848 than LPS or CpG1826
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(Fig. 5a). IgG anti-U1A autoantibodies were produced
spontaneously by sorted PC and PB, and autoantibody
production was enhanced (substantially in the MB and
PB subsets, with a similar trend in the PC subset) by
culturing with R848 (Fig. 5b). The NB subset did not
produce IgG anti-U1A after treatment with R848. In the
sMB subset, total IgG production was enhanced consid-
erably by R848 as well as LPS and CpG1826 (Fig. 5c). In
contrast, IgG anti-U1A autoantibody production by this
subset was enhanced more strongly by R848 than by
LPS or CpG1826 treatment.
The possibility that pristane treatment might pro-
mote production of IgM anti-U1A autoantibodies also
was of interest. However, serum levels of IgM anti-
nRNP/Sm (which includes anti-U1A), and anti-Su,
anti-chromatin, and anti-dsDNA, all were negligible
in pristane-treated mice (Fig. 5d). Thus, it proved dif-
ficult technically to evaluate IgM autoantibody pro-
duction from NB in culture.
Role of R848-stimulated B cell signaling pathways in IgG
production
Upon TLR7 ligation, several signaling pathways are
activated via MyD88, including the IRF5/7, NF-κB,
p38-MAPK, and PI3K/AKT/mTOR pathways [28, 29].
To investigate the role of NF-κB and p38-MAPK, we stim-
ulated B cells with R848 in the presence or absence of
JSH23 (a selective NF-κB classical pathway inhibitor) or
SB203580 (a selective p38 MAPK inhibitor). Both JSH23
and SB203580 decreased R848-stimulated IgG production
by B cells from pristane-treated (Fig. 6a) and untreated
(Fig. 6b) mice, suggesting that both the classical NF-κB
and p38-MAPK pathways are involved in TLR7-stimulated
IgG production in murine B cells.
Discussion
Patients with SLE can produce extraordinary levels
(titers ≥1:106 or more) of IgG autoantibodies against cer-
tain RNA-protein autoantigens, such as U1 snRNPs [1].
Fig. 4 R848-stimulated proliferation, survival, and Ig production by B cell subsets from pristane-treated mice. Splenic naïve B cells (NB), switched B
memory cells (sMB), switched plasmablasts (sPB) and plasma cells (PC) were flow-sorted from pristane-treated or PBS-treated mice. a Sorted B cell
subsets from PBS-treated mice were cultured for 3 days with R848. Proliferation was assessed by flow cytometry of carboxyfluorescein diacetate
succinimidyl ester (CFSE)-loaded cells (values are geometric means). b Sorted B cell subsets from PBS-treated mice were cultured for 24 h in the
presence or absence of R848 and cell death was assessed by 7-AAD staining (flow cytometry). Data are representative of two separate experiments.
c Sorted B cell subsets from pristane treated mice were stimulated with R848 or PBS for 10 days. IgG and IgM were measured in culture supernatants
by ELISA. Data are representative of three separate experiments: *p <0.05; ***p <0.001 (paired Student t test)
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Once present, they usually are maintained at high levels
for life, consistent with serological memory mediated by
long-lived PC, MB, or both. We recently identified sMB-
like cells and PC specific for U1A, a component of the U1
snRNP, in BM and spleen of mice with pristane-induced
lupus [15]. We examined the role of TLR7 in generating
anti-U1A PB and PC from CD19+CD138−IgD−IgM−
switched memory-like B cells in pristane-induced lupus.
MB from pristane-treated mice produced more IgG than
control MB when stimulated with the synthetic TLR7 lig-
and R848 and expressed higher levels of Tlr7, potentially
explaining their hyper-responsiveness to R848. Although
MB from both untreated and pristane-treated mice pro-
duced IgG when stimulated in vitro with R848 (possibly
along with antigen released from dying cells in culture),
only those from pristane-treated mice produced IgG when
co-cultured with apoptotic cells. TLR7 ligand treatment
also induced IgG anti-U1A autoantibody production, sug-
gesting that endogenous TLR7 ligands might help to
maintain autoantibody production. The potential role of
endogenous TLR ligands also is supported by the fact that
autoantibodies develop in germ-free mice[30] and are ab-
sent in Fas-deficient mice[31]. R848-driven and apoptotic
cell-driven IgG production was blocked by an inhibitory
oligodeoxyribonucleotide specific for TLR7 (Fig. 1c), and
IgG production was decreased in TLR7−/− vs. wild type B
cells after stimulation with apoptotic cells (Fig. 1d), con-
sistent with the role of TLR7 ligands in promoting
Fig. 5 R848 preferentially stimulates anti-U1A autoantibody production by splenic B cells from pristane-treated mice. a Purified (magnetic beads)
splenic CD19+ B from pristane-treated mice were stimulated with toll-like receptor (TLR) agonists (R848, LPS, or CpG1826) for 10 days. IgG anti-U1A
autoantibodies were measured in culture supernatants (ELISA). b Flow-sorted plasma cells (PC), switched plasmablasts (PB), switched memory B cells
(MB), and naïve B cells (NB) were stimulated with PBS or R848 for 10 days, and IgG anti-U1A was measured (ELISA). c Flow-sorted splenic sMB cells were
stimulated with TLR ligands for 10 days, and total IgG and IgG anti-U1A levels were measured in culture supernatants (ELISA). Data are representative
of three experiments. d BALB/c and BALB/c TLR7−/− mice were treated with pristane and serum IgG and IgM autoantibody levels were determined
(ELISA) 30 weeks later (1:40 serum dilution): *p <0.05, **p <0.01; ***p <0.001 (paired Student t test)
Han et al. Arthritis Research & Therapy  (2015) 17:384 Page 9 of 13
terminal B cell differentiation. JSH23, an inhibitor of the
canonical NFκB pathway, and the p38 MAPK inhibitor
SB203580 also inhibited R848-driven IgG production.
These studies suggest that increased Tlr7 expression by
sMB from pristane-treated mice allows these cells to
respond more vigorously to weak TLR7 signals, helping to
maintain autoantibody production.
Production of anti-U1A autoantibodies by PC/PB and
memory-like B cells
Serological memory is mediated by long-lived PC as well
as MB, which upon antigenic challenge develop into PC
[32]. The importance of TLR signaling in generating T
cell-dependent, antigen-specific antibody responses is
controversial [33, 34], as is the suggestion that sero-
logical memory is maintained by polyclonal B cell intrin-
sic, TLR-mediated, activation of post-germinal center
MB [11, 35, 36]. The requirement for TLR signaling may
differ depending on the nature of the antigen [11]. In
particular, although dendritic cell, but not B cell, MyD88
expression is required to enhance antibody responses
using a soluble TLR9 ligand as adjuvant, when the TLR9
ligand is incorporated into a virus-like particle it en-
hances primary T cell-dependent IgG2a/IgG2c produc-
tion in a B cell intrinsic, MyD88/TLR9-dependent,
manner [37, 38]. Similarly, TLR7 and MyD88 promote
primary IgG2a/IgG2c responses to influenza virus by in-
ducing IFNα production [39].
Cellular RNA-protein complexes, such as U1 snRNPs,
resemble virus-like particles. When incorporated into
U1 snRNPs, U1 RNA is highly resistant to degradation
by ribonuclease (W Reeves, unpublished observation),
which may delay endosomal degradation, potentially
facilitating its association with TLR7. Like antiviral re-
sponses, primary autoantibody responses are abolished
in MyD88-deficient or TLR7-deficient mice [4, 20, 40].
However, less is known about the role of TLR7 in driv-
ing the production of IgG autoantibodies by sMB. Unlike
human B cells, in which a CD27+ memory subset (and
CD27− memory subsets) can be identified readily by
their cell surface phenotype [41], the phenotype of
murine sMB is less well characterized [42, 43]. We ex-
amined CD19+CD138−IgM−IgD− switched memory-like
B cells, which may contain both antigen-experienced
sMB and activated IgG-expressing non-memory cells.
This population was expanded in pristane-treated mice
(Fig. 2a) and expressed lower levels of class II MHC and
CIITA than NB but higher than PB (Fig. 3b).
The sMB population did not secrete autoantibodies
spontaneously, but upon TLR7 ligand exposure pro-
duced IgG anti-U1A (Fig. 5b). In contrast, NB (CD19+
CD138−IgM+IgD+) did not secrete IgG anti-U1A when
activated by R848. The anti-U1A B cells identified here
differ from the long-lived, low affinity, anti-Sm-specific,
mature follicular B-2 cells identified previously in 2-
12H/Vκ8L chain transgenic mice [44], as they were not
anergic, but rather were hyper-responsive to TLR ligands
(Fig. 5). Anti-U1A B cells in pristane-treated mice also
differ from autoreactive B cells in 2-12H chain trans-
genic mice, which do not spontaneously secrete anti-Sm
autoantibodies and have a developmental block at the
transitional B cell stage [45]. Some of these cells escape
and proceed to an early pre-PC stage, but are subject to
tolerance and do not secrete autoantibodies in non-
autoimmune mice [46]. Interestingly, this tolerance
checkpoint is defective in MRL/lpr mice, possibly due to
increased B cell signaling. It is interesting to speculate
that enhanced TLR7 signaling in B cells from pristane-
treated mice might allow autoreactive B cells to escape
this early pre-PC checkpoint. Consistent with that possi-
bility, spleen from pristane-treated mice contained an
sPB subset (CD19+CD138+IgM−IgD−) that secreted anti-
Fig. 6 p38 mitogen-activated protein kinase (MAPK) and NF-kB pathways in R848 stimulated IgG production. Purified (magnetic beads) splenic
CD19+ B cells from pristane-treated mice (a) and PBS-treated mice (b) were stimulated with R848 alone or with R848 plus p38 MAPK inhibitor
SB203580 (SB80) (10 μM) or NF-κB classical pathway inhibitor JSH23 (5 μM) for 10 days. IgG in supernatants was measured with ELISA: *p <0.05;
**p <0.01 (paired t test) vs. dimethyl sulfoxide (DMSO)/R848 control
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U1A autoantibodies spontaneously but had enhanced
autoantibody production in response to R848 (Fig. 5b).
In view of the hyper-responsiveness of B cells from
pristane-treated mice to synthetic TLR7 ligands and
apoptotic cells (Fig. 1b), we hypothesize that autologous
TLR7 ligands derived from dead cells accumulating
within the tissues may help drive the CD19+CD138−
IgM−IgD− (sMB) subset in pristane-treated mice to
undergo terminal differentiation in vivo. However, further
studies will be necessary to confirm that possibility.
B cells from pristane-treated mice are hyper-responsive
to TLR7 ligands
B cells from pristane-treated mice were hypersensitive to
R848-stimulated IgG production (Fig. 1a). Interestingly,
apoptotic cells also stimulated IgG production in B cells
from pristane-treated, but not PBS-treated mice (Fig. 1b).
Potential explanations include 1) increased TLR7 expres-
sion by pristane-treated B cells, 2) altered signaling
downstream of TLR7, or 3) activation of signaling path-
ways in pristane-treated B cells that act synergistically
with TLR7 signaling to promote B cell differentiation or
IgG secretion. Tlr7 gene dosage strongly affects B cell
activation and the development of autoantibodies to
RNA-protein complexes [24, 47–49]. In addition in-
creased Tlr7 gene dosage promotes dendritic cell pro-
liferation and cytokine secretion, further upregulating
Tlr7 expression and serving as a positive feedback loop
exacerbating autoimmunity [47].
TLR7 expression is upregulated in PBMCs and B cells
from SLE patients [50]. Although we suspected that
pristane treatment might increase B cell Tlr7 expression,
expression was similar in purified total CD19+ cells from
pristane-treated mice and PBS-treated controls (Fig. 1g).
However, Tlr7 expression was increased in sMB, PC, and
possibly sPB from pristane-treated mice, but not in NB
(the most abundant splenic B cell subset) (Fig. 3c).
Switched MB (Fig. 3e) and to a lesser degree PB/PC
(Fig. 3d) from pristane-treated mice produced more
R848-stimulated IgG than the same subsets from PBS-
treated mice. In contrast, NB did not produce IgG in re-
sponse to R848 but did make IgM, suggesting that TLR7
ligand stimulation could not drive class switch recom-
bination in NB. Interestingly, although serum from
pristane-treated mice contained high levels of IgG auto-
antibodies, levels of IgM autoantibodies were minimal
(Fig. 5d), consistent with the possibility that autore-
activity was acquired through somatic hypermutation
occurring either in germinal centers or extrafollicular.
Increased Tlr7 expression in sMB along with increased
numbers of sMB may explain the enhanced R848-
stimulated IgG production by B cells from pristane-
treated mice (Fig. 1e). As IFN-I stimulates Tlr7 expression
in murine B cells and other cell types [51, 52], the strong
IFN-I response in pristane-treated mice [7] may increase
Tlr7 expression in sMB (Fig. 3c). It is unclear why NB
from pristane-treated mice did not exhibit increased Tlr7
expression and it will be of interest in the future to see if
the NB subset is deficient in Ifnar1/Ifnar2 expression or
expression of components of the downstream signaling
pathway.
At present, we cannot exclude the possibility that the
hyper-responsiveness of B cells from pristane-treated mice
reflects altered signaling downstream of TLR7 or in other
signaling pathways. For example, FcγRIIB deficiency
enhances BCR/TLR7-stimulated B cell proliferative re-
sponses [53] and IFNAR/BCR signaling regulates TLR7
responses via activation of the PI3K/Akt/mammalian
target of rapamycin (mTOR) signaling pathways [54]. Also
accumulating evidence suggests that miRNAs fine-tune
TLR signaling pathways by targeting adaptor mole-
cules and TLRs themselves. In particular, miR3148 is
predicted to bind the TLR7 3′ UTR, and a polymorphism
(rs3853839) may regulate TLR7 expression in SLE [55].
Finally, we cannot exclude a role of enhanced proliferation
and/or prolonged survival of splenic PBs (Fig. 4).
Conclusions
In summary, a population of B cells with a switched
memory-like phenotype is expanded in pristane-treated
mice, expresses increased levels of Tlr7, and is hyper-
responsive to synthetic TLR7 ligands and apoptotic cells.
This population contains B cells that do not secrete
immunoglobulin under resting conditions, but can be
driven by TLR7 ligands to produce IgG anti-U1A (RNP)
autoantibodies in an NFκB and p38 MAPK-dependent
manner. In view of the marked accumulation of dead
cells in lupus bone marrow (16) and other sites, we
hypothesize that persistently high levels of anti-RNP/Sm
autoantibodies in lupus may be maintained, in part,
through the chronic activation of sMB by uncleared
apoptotic cells.
Additional file
Additional file 1: Figure S1. Responsiveness of terminally differentiated
plasma cells to R848. a Tlr1-9 expression in 2.73 hybridoma and SP2/0
non-secreting myeloma cells (PCR). b Surface staining of 2.73 and SP2/0 for
CD138, I-A/I-E, B220 and CD19 (flow cytometry). c Six different hybridoma
cell lines (1: 2.73; 2:172.4; 3:11B11; 4:Pab101; 5:111; 6:162) were stimulated
with toll-like receptor (TLR) agonists, R848 (TLR7), lipopolysaccharide (LPS)
(TLR4), or CpG1826 (TLR9) for 3 days labeled with carboxyfluorescein
diacetate succinimidyl ester (CFSE) followed by stimulationd for 3 days with
R848. Cell proliferation was assessed by measuring CFSE fluorescence (values
are geometric means). (TIFF 1085 kb)
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